niacinamide and Carcinoma, Anaplastic studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

Excerpt	Relevance	Reference
" Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash."	9.17	Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. ( Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ, 2013)
"We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)."	9.17	Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013)
"Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma."	9.15	Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011)
" Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-beta, B-Raf, and C-Raf, has shown to be active in preclinical models of cholangiocarcinoma."	9.14	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. ( Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S, 2010)
"Sorafenib had minimal activity in patients with uterine carcinoma."	9.14	A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. ( Agamah, E; Elit, L; Fleming, GF; Huo, D; Knost, JA; Morgan, RJ; Nimeiri, HS; Oza, AM; Vokes, EE; Wade, JL, 2010)
"We measured serum thyroxine (T4), free T4, 3,5,3-triiodothyronine (T3), free T3, reverse T3 (rT3), and TSH concentrations at baseline and after 26 wk in 21 patients with progressive nonmedullary thyroid carcinoma treated with sorafenib."	9.14	Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. ( Abdulrahman, RM; Corssmit, EP; Gelderblom, H; Hoftijzer, H; Hovens, GC; Kapiteijn, E; Pereira, AM; Reiners, C; Romijn, JA; Smit, JW; Verburg, E; Verloop, H; Visser, TJ, 2010)
"Carbogen and nicotinamide have been evaluated in a phase II study as hypoxia-modifying agents during radical radiotherapy for bladder cancer using a standard daily 20-fraction schedule."	9.08	Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. ( Cladd, H; Goodchild, K; Hoskin, PJ; Phillips, H; Powell, ME; Rojas, A; Saunders, MI; Stratford, MR, 1997)
" Sorafenib is a small-molecule multikinase inhibitor used in radioactive iodine ((131)I)-refractive papillary thyroid carcinoma."	7.80	Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. ( Ewig, JM; Iyer, P; Mayer, JL, 2014)
" We report a case of a 60-year-old woman who developed left renal artery stenosis associated with renal atrophy in the context of metastatic papillary thyroid carcinoma treated with sorafenib."	7.79	Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. ( Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H, 2013)
" We investigated the effect of the hypoxia-modulating agents nicotinamide and carbogen on tumor hypoxia, tumor blood perfusion, and proliferative activity in liver metastases of the murine colon carcinoma line C26a."	7.73	Modulation of hypoxia in murine liver metastases of colon carcinoma by nicotinamide and carbogen. ( Bussink, J; Heerschap, A; Kaanders, JH; Lok, J; Punt, CJ; van der Kogel, AJ; van Laarhoven, HW; Verhagen, I, 2005)
"Sorafenib has clinically relevant antitumor activity in patients with progressive metastatic or locally advanced radio-iodine refractory differentiated thyroid cancer."	6.77	Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. ( Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW, 2012)
"There is a distinct increase in the rate of occurrence of adverse effects of sorafenib when used in differentiated thyroid cancer compared with renal and hepatocellular cancer."	6.53	Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers. ( Jaffry, A; Jean, GW; Khan, SA; Mani, RM, 2016)
"Everolimus was neither additive nor syngergistic in combination with sorafenib or AZD6244."	5.38	Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. ( Agarwal, K; Brendel, VJ; Jarjoura, D; Koh, YW; Koo, BS; McCarty, SK; Porter, K; Ringel, MD; Saji, M; Shah, MH; Wang, C, 2012)
" Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash."	5.17	Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. ( Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ, 2013)
"We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)."	5.17	Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013)
"To evaluate the tolerability and efficacy of sorafenib in patients with thyroid carcinoma."	5.15	Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. ( Ahmed, M; Barbachano, Y; Harrington, KJ; Hickey, J; Marais, R; Newbold, KL; Nutting, CM; Riddell, A; Viros, A, 2011)
"Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma."	5.15	Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011)
" Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-beta, B-Raf, and C-Raf, has shown to be active in preclinical models of cholangiocarcinoma."	5.14	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. ( Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S, 2010)
"Sorafenib had minimal activity in patients with uterine carcinoma."	5.14	A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. ( Agamah, E; Elit, L; Fleming, GF; Huo, D; Knost, JA; Morgan, RJ; Nimeiri, HS; Oza, AM; Vokes, EE; Wade, JL, 2010)
"We measured serum thyroxine (T4), free T4, 3,5,3-triiodothyronine (T3), free T3, reverse T3 (rT3), and TSH concentrations at baseline and after 26 wk in 21 patients with progressive nonmedullary thyroid carcinoma treated with sorafenib."	5.14	Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. ( Abdulrahman, RM; Corssmit, EP; Gelderblom, H; Hoftijzer, H; Hovens, GC; Kapiteijn, E; Pereira, AM; Reiners, C; Romijn, JA; Smit, JW; Verburg, E; Verloop, H; Visser, TJ, 2010)
"Carbogen and nicotinamide have been evaluated in a phase II study as hypoxia-modifying agents during radical radiotherapy for bladder cancer using a standard daily 20-fraction schedule."	5.08	Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. ( Cladd, H; Goodchild, K; Hoskin, PJ; Phillips, H; Powell, ME; Rojas, A; Saunders, MI; Stratford, MR, 1997)
"Sorafenib, a multikinase inhibitor has recently been approved for the treatment of radio-iodine refractory thyroid carcinoma."	3.81	Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. ( Chen, G; Derwahl, M; Nicula, D; Renko, K, 2015)
" Sorafenib is a small-molecule multikinase inhibitor used in radioactive iodine ((131)I)-refractive papillary thyroid carcinoma."	3.80	Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. ( Ewig, JM; Iyer, P; Mayer, JL, 2014)
"THERE WERE 62 PATIENTS (37 MEN, MEAN AGE: 61 years) treated with sorafenib (62%), sunitinib (22%), and vandetanib (16%) outside of clinical trials; 22 had papillary, five had follicular, five had Hürthle cell, 13 had poorly differentiated, and 17 had medullary thyroid carcinoma (MTC)."	3.80	Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. ( Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M, 2014)
" We report a case of a 60-year-old woman who developed left renal artery stenosis associated with renal atrophy in the context of metastatic papillary thyroid carcinoma treated with sorafenib."	3.79	Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. ( Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H, 2013)
"Before and after the last week of sorafenib therapy, 20 patients with progressive differentiated thyroid carcinoma received a standard dose regimen of two injections 0."	3.79	Sorafenib therapy decreases the clearance of thyrotropin. ( Dekkers, OM; Smit, JW; Verloop, H, 2013)
"Multikinase inhibitors (MKIs) sunitinib and sorafenib have become a standard of care for metastatic renal cell carcinoma (mRCC)."	3.77	Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. ( Canipari, C; Chen, K; Duh, MS; Imarisio, I; Neary, M; Paglino, C; Porta, C, 2011)
" We investigated the effect of the hypoxia-modulating agents nicotinamide and carbogen on tumor hypoxia, tumor blood perfusion, and proliferative activity in liver metastases of the murine colon carcinoma line C26a."	3.73	Modulation of hypoxia in murine liver metastases of colon carcinoma by nicotinamide and carbogen. ( Bussink, J; Heerschap, A; Kaanders, JH; Lok, J; Punt, CJ; van der Kogel, AJ; van Laarhoven, HW; Verhagen, I, 2005)
"Sorafenib has clinically relevant antitumor activity in patients with progressive metastatic or locally advanced radio-iodine refractory differentiated thyroid cancer."	2.77	Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. ( Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW, 2012)
"Full pharmacokinetic profiles of nicotinamide concentrations in plasma were analyzed repeatedly in 15 patients to determine the inter- and intra-patient variability in peak plasma concentrations and the optimum times for administering nicotinamide as a radiosensitizer."	2.69	Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. ( Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR, 1998)
"There is a distinct increase in the rate of occurrence of adverse effects of sorafenib when used in differentiated thyroid cancer compared with renal and hepatocellular cancer."	2.53	Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers. ( Jaffry, A; Jean, GW; Khan, SA; Mani, RM, 2016)
"Sorafenib (Nexavar) is a multikinase inhibitor, which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of targets present in the tumor cell [c-RAF (proto-oncogene serine/threonine-protein kinase), BRAF, (V600E)BRAF, c-KIT, and FMS-like tyrosine kinase 3] and in tumor vessels (c-RAF, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, and platelet-derived growth factor receptor β)."	2.49	Sorafenib and thyroid cancer. ( Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Santini, F; Ulisse, S, 2013)
" Additional secondary endpoints are postprogression survival from time of symptomatic progression, duration of and response to each systemic treatment regimen and dosing of sorafenib throughout the treatment period."	1.46	Timing of multikinase inhibitor initiation in differentiated thyroid cancer. ( Brose, MS; DeSanctis, Y; Fellous, M; Lin, CC; Pitoia, F; Schlumberger, M; Smit, J; Sugitani, I; Tori, M, 2017)
"Sorafenib has proven efficacy in advanced differentiated thyroid cancer (DTC), but many patients must reduce the dose or discontinue treatment because of toxicity."	1.40	Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. ( Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK, 2014)
"Everolimus was neither additive nor syngergistic in combination with sorafenib or AZD6244."	1.38	Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. ( Agarwal, K; Brendel, VJ; Jarjoura, D; Koh, YW; Koo, BS; McCarty, SK; Porter, K; Ringel, MD; Saji, M; Shah, MH; Wang, C, 2012)
"Both the metastasis and the primary thyroid tumor are positive for BRAF(V600E) mutation."	1.38	Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. ( Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS, 2012)
"Patients with progressive refractory thyroid cancer are potential candidates for clinical trials using tyrosine kinase inhibitors (TKIs), and a promising proportion of patients in these trials have achieved stable disease."	1.37	Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. ( Bousquet, G; Faugeron, I; Hindie, E; Lussato, D; Toubert, ME; Vercellino, L, 2011)
"Treatment with sorafenib enhanced TRAIL-induced Annexin V staining and release of mitochondrial cytochrome c and AIF."	1.36	Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. ( Huang, S; Sinicrope, FA, 2010)
"Sorafenib was recently approved for the treatment of renal cell carcinoma."	1.33	Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. ( Boogaerts, M; Cools, J; Folens, C; Lierman, E; Marynen, P; Mentens, N; Scheers, W; Stover, EH; Van Miegroet, H; Vandenberghe, P, 2006)
" A next group of 87 patients received 60 mg/kg nicotinamide in combination with domperidone."	1.31	Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. ( Bussink, J; Folkes, LK; Kaanders, JH; Stratford, MR; van der Kogel, AJ, 2002)

Research

Studies (66)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Number of Participants That Experienced Adverse Events to Characterize the Safety Profile of BAY 43-9006

Timeframe	Studies, this research(%)	All Research%
pre-1990	14 (21.21)	18.7374
1990's	5 (7.58)	18.2507
2000's	11 (16.67)	29.6817
2010's	34 (51.52)	24.3611
2020's	2 (3.03)	2.80

Authors	Studies
Lim, RK	1
Weinstock, MA	1
Kahn, B	1
Borrelli, M	1
Libby, T	1
Iyer, P	1
Mayer, JL	1
Ewig, JM	1
Shawa, H	1
Busaidy, NL	2
Schellingerhout, D	1
Habra, MA	2
Fallahi, P	1
Ferrari, SM	1
Santini, F	1
Corrado, A	1
Materazzi, G	1
Ulisse, S	1
Miccoli, P	1
Antonelli, A	1
Massicotte, MH	1
Brassard, M	1
Claude-Desroches, M	1
Borget, I	1
Bonichon, F	1
Giraudet, AL	1
Do Cao, C	1
Chougnet, CN	1
Leboulleux, S	1
Baudin, E	1
Schlumberger, M	2
de la Fouchardière, C	1
Nguyen, TV	1
Sleiman, M	1
Moriarty, T	1
Herrick, WG	1
Peyton, SR	1
Dadu, R	1
Waguespack, SG	1
Sherman, SI	2
Hu, MI	1
Jimenez, C	1
Ying, AK	1
Bassett, RL	1
Cabanillas, ME	1
Chen, G	1
Nicula, D	1
Renko, K	1
Derwahl, M	1
Jean, GW	1
Mani, RM	1
Jaffry, A	1
Khan, SA	1
Mirantes, C	1
Dosil, MA	1
Eritja, N	1
Felip, I	1
Gatius, S	1
Santacana, M	1
Matias-Guiu, X	1
Dolcet, X	1
Brose, MS	1
Smit, J	1
Lin, CC	1
Pitoia, F	1
Fellous, M	1
DeSanctis, Y	1
Tori, M	1
Sugitani, I	1
Stenner, F	1
Liewen, H	1
Zweifel, M	1
Weber, A	1
Tchinda, J	1
Bode, B	1
Samaras, P	1
Bauer, S	1
Knuth, A	1
Renner, C	1
Li, XF	1
Chen, Q	1
Huang, WX	1
Ye, YB	1
Bellmunt, J	1
Calvo, E	1
Castellano, D	1
Climent, MA	1
Esteban, E	1
García del Muro, X	1
González-Larriba, JL	1
Maroto, P	1
Trigo, JM	1
Bengala, C	1
Bertolini, F	1
Malavasi, N	1
Boni, C	1
Aitini, E	1
Dealis, C	1
Zironi, S	1
Depenni, R	1
Fontana, A	1
Del Giovane, C	1
Luppi, G	1
Conte, P	1
Alfano, RW	1
Leppla, SH	1
Liu, S	1
Bugge, TH	1
Ortiz, JM	1
Lairmore, TC	1
Duesbery, NS	1
Mitchell, IC	1
Nwariaku, F	1
Frankel, AE	1
Boonstra, JJ	1
van Marion, R	1
Beer, DG	1
Lin, L	1
Chaves, P	1
Ribeiro, C	1
Pereira, AD	1
Roque, L	1
Darnton, SJ	1
Altorki, NK	1
Schrump, DS	1
Klimstra, DS	1
Tang, LH	1
Eshleman, JR	1
Alvarez, H	1
Shimada, Y	1
van Dekken, H	1
Tilanus, HW	1
Dinjens, WN	1
Nimeiri, HS	1
Oza, AM	1
Morgan, RJ	1
Huo, D	1
Elit, L	1
Knost, JA	1
Wade, JL	1
Agamah, E	1
Vokes, EE	1
Fleming, GF	1
Puca, R	1
Nardinocchi, L	1
Starace, G	1
Rechavi, G	1
Sacchi, A	1
Givol, D	1
D'Orazi, G	1
Huang, S	1
Sinicrope, FA	1
Abdulrahman, RM	2
Verloop, H	2
Hoftijzer, H	1
Verburg, E	1
Hovens, GC	1
Corssmit, EP	2
Reiners, C	1
Gelderblom, H	1
Pereira, AM	1
Kapiteijn, E	2
Romijn, JA	1
Visser, TJ	1
Smit, JW	3
Ullén, A	2
Farnebo, M	1
Thyrell, L	1
Mahmoudi, S	1
Kharaziha, P	2
Lennartsson, L	1
Grandér, D	2
Panaretakis, T	2
Nilsson, S	2
Chen, L	1
Shen, Y	1
Luo, Q	1
Yu, Y	1
Lu, H	1
Zhu, R	1
Fratto, ME	1
Santini, D	1
Vincenzi, B	1
Silvestris, N	1
Azzariti, A	1
Tommasi, S	1
Zoccoli, A	1
Galluzzo, S	1
Maiello, E	1
Colucci, G	1
Tonini, G	1
Toubert, ME	1
Vercellino, L	1
Faugeron, I	1
Lussato, D	1
Hindie, E	1
Bousquet, G	1
Porta, C	1
Paglino, C	1
Imarisio, I	1
Canipari, C	1
Chen, K	1
Neary, M	1
Duh, MS	1
Ahmed, M	1
Barbachano, Y	1
Riddell, A	1
Hickey, J	1
Newbold, KL	1
Viros, A	1
Harrington, KJ	1
Marais, R	1
Nutting, CM	1
Koh, YW	1
Shah, MH	1
Agarwal, K	1
McCarty, SK	1
Koo, BS	1
Brendel, VJ	1
Wang, C	1
Porter, K	1
Jarjoura, D	1
Saji, M	1
Ringel, MD	1
Rodriguez, P	1
Li, Q	1
Rundqvist, H	1
Björklund, AC	1
Augsten, M	1
Egevad, L	1
Wiklund, P	1
Kroemer, G	1
Missana, A	1
Meyer, P	1
Alzahrani, AS	1
AlQaraawi, A	1
Al Sohaibani, F	1
Almanea, H	1
Abalkhail, H	1
Mariniello, B	1
Rosato, A	1
Zuccolotto, G	1
Rubin, B	1
Cicala, MV	1
Finco, I	1
Iacobone, M	1
Frigo, AC	1
Fassina, A	1
Pezzani, R	1
Mantero, F	1
Matsuse, M	1
Mitsutake, N	1
Tanimura, S	1
Ogi, T	1
Nishihara, E	1
Hirokawa, M	1
Fuziwara, CS	1
Saenko, VA	1
Suzuki, K	1
Miyauchi, A	1
Yamashita, S	1
Schneider, TC	1
Morreau, H	1
Savvides, P	1
Nagaiah, G	1
Lavertu, P	1
Fu, P	1
Wright, JJ	1
Chapman, R	1
Wasman, J	1
Dowlati, A	1
Remick, SC	1
Dekkers, OM	1
Xue, C	1
Huang, Y	1
Huang, PY	1
Yu, QT	1
Pan, JJ	1
Liu, LZ	1
Song, XQ	1
Lin, SJ	1
Wu, JX	1
Zhang, JW	1
Zhao, HY	1
Xu, F	1
Liu, JL	1
Hu, ZH	1
Zhao, LP	1
Zhao, YY	1
Wu, X	1
Zhang, J	1
Ma, YX	1
Zhang, L	1
Cohen, SM	1
Mukerji, R	1
Timmermann, BN	1
Samadi, AK	1
Cohen, MS	1
Bussink, J	3
Stratford, MR	3
van der Kogel, AJ	4
Folkes, LK	1
Kaanders, JH	4
HUDACK, ED	1
EROS, DE	1
BRUMMOND, DO	1
FRIEDLAND, IM	1
FULLER, L	1
DIETRICH, LS	1
PRINA, C	1
MAGRASSI, B	1
ROVETA, G	1
PUETTER, J	1
FEINSTEIN, RN	1
COULON, M	1
THOMPSON, E	1
HAVAS, HF	1
BERRY, LJ	1
SMYTHE, DS	1
KUN, E	1
LANGER, B	1
ULRICH, B	1
HOLZER, H	1
GRUNICKE, H	1
HILZ, H	1
RUETER, J	1
OLDEKOP, M	1
WUEPPEN, I	1
LUEHRS, W	1
CHROMETZKA, K	1
Heim, M	1
Sharifi, M	1
Hilger, RA	1
Scheulen, ME	1
Seeber, S	1
Strumberg, D	1
van Laarhoven, HW	1
Lok, J	1
Verhagen, I	1
Punt, CJ	1
Heerschap, A	1
Salvatore, G	1
De Falco, V	1
Salerno, P	1
Nappi, TC	1
Pepe, S	1
Troncone, G	1
Carlomagno, F	1
Melillo, RM	1
Wilhelm, SM	1
Santoro, M	1
Lierman, E	1
Folens, C	1
Stover, EH	1
Mentens, N	1
Van Miegroet, H	1
Scheers, W	1
Boogaerts, M	1
Vandenberghe, P	1
Marynen, P	1
Cools, J	1
Kang, HT	1
Lee, HI	1
Hwang, ES	1
Pour, PM	1
Lawson, T	1
Hoskin, PJ	1
Saunders, MI	1
Phillips, H	1
Cladd, H	1
Powell, ME	1
Goodchild, K	1
Rojas, A	2
Bernier, J	1
Denekamp, J	1
Dennis, MF	1
Bieri, S	1
Hagen, F	1
Kocagöncü, O	1
Bolla, M	1
Pop, LA	1
Marres, HA	1
Liefers, J	1
van den Hoogen, FJ	1
van Daal, WA	1
Honess, DJ	1
Hill, SA	1
Collingridge, DR	1
Edwards, B	1
Brauers, G	1
Powell, NA	1
Chaplin, DJ	1
Wood, PJ	1
Counsell, CJ	1
Bremner, JC	1
Horsman, MR	1
Adams, GE	1
Urade, M	1
Sugi, M	1
Miyazaki, T	1
Buch, L	1
Streeter, D	1
Halpern, RM	1
Simon, LN	2
Stout, MG	1
Smith, RA	1
Swiatek, KR	1
Chao, KL	1
Schievelbein, H	1
Kuntze, I	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors[NCT02303444]		667 participants (Actual)	Observational	2015-04-08	Completed
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma[NCT00887107]	Phase 2	32 participants (Actual)	Interventional	2007-10-31	Completed
Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid[NCT00126568]	Phase 2	20 participants (Actual)	Interventional	2005-06-30	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The safety and toxicity profile of BAY 43-9006 as measured by toxicity grades of adverse events. (NCT00126568)
Timeframe: 27 months

Overall Survival Was Measured From the Date of Outset of Treatment to the Date of Death.

Progression Free Survival Was Measured From the Date of Outset of Treatment to the Date of Disease Progression.

Number of Patients With Response to Treatment Measured by RECIST Criteria

Intervention	Participants (Count of Participants)
Treatment (Sorafenib Tosylate)	20

Intervention	months (Median)
BAY 43-9006	3.9

Intervention	months (Median)
BAY 43-9006	1.9

Response evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. The patient's best response depends on the achievement of measurement and confirmation criteria of Complete Response (CR), Stable Disease (SD), Partial Response (PR) or Progressive Disease (PD). Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques (CT, MRI, x-ray) or as >10 mm with spiral CT scan. (NCT00126568)
Timeframe: at 6 months after treatment

Article	Year
A Narrative Review of Nicotinamide Adenine Dinucleotide (NAD)+ Intermediates Nicotinamide Riboside and Nicotinamide Mononucleotide for Keratinocyte Carcinoma Risk Reduction. Journal of drugs in dermatology : JDD, 2022, Oct-01, Volume: 21, Issue:10 Topics: Carcinoma; Humans; Keratinocytes; NAD; Niacinamide; Nicotinamide Mononucleotide; Pyridinium Compound	2022
Sorafenib and thyroid cancer. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2013, Volume: 27, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Neuroendocrine; Carci	2013
Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers. JAMA oncology, 2016, Volume: 2, Issue:4 Topics: Antineoplastic Agents; Carcinoma; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; T	2016
Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma	2011
ARCON: a novel biology-based approach in radiotherapy. The Lancet. Oncology, 2002, Volume: 3, Issue:12 Topics: Animals; Carbon Dioxide; Carcinoma; Cell Cycle; Cell Hypoxia; Clinical Trials as Topic; Dose Fractio	2002
Early clinical studies of novel therapies for thyroid cancers. Endocrinology and metabolism clinics of North America, 2008, Volume: 37, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma;	2008

Article	Year
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. British journal of cancer, 2010, Jan-05, Volume: 102, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Bilia	2010
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecologic oncology, 2010, Volume: 117, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinosarcoma;	2010
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:8 Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma; Female; Humans; Hypothyroidism; Male; Middle	2010
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disea	2011
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. European journal of endocrinology, 2011, Volume: 165, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Female; Humans; Male; Middle Aged;	2011
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. European journal of endocrinology, 2012, Volume: 167, Issue:5 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Aged, 80 and over; Antineoplastic Agents; Benz	2012
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid : official journal of the American Thyroid Association, 2013, Volume: 23, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Drug Eruptions; Drug Resistance, Multiple; Drug Resis	2013
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv	2013
Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. British journal of cancer, 1997, Volume: 76, Issue:2 Topics: Aged; Carbon Dioxide; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Male; Middl	1997
Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1998, Volume: 48, Issue:2 Topics: Administration, Oral; Area Under Curve; Carbon Dioxide; Carcinoma; Carcinoma, Non-Small-Cell Lung; C	1998

Article	Year
Nicotinamide for Keratinocyte Carcinoma Chemoprevention: A Nationwide Survey of Mohs Surgeons. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2021, 11-01, Volume: 47, Issue:11 Topics: Carcinoma; Humans; Keratinocytes; Mohs Surgery; Niacinamide; Surgeons	2021
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:1 Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male;	2014
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. BMJ case reports, 2013, May-15, Volume: 2013 Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged	2013
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. European journal of endocrinology, 2014, Volume: 170, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents;	2014
Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening. Biomaterials, 2014, Volume: 35, Issue:22 Topics: Antineoplastic Agents; Biomechanical Phenomena; Breast; Breast Neoplasms; Carcinoma; Cell Line, Tumo	2014
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. The oncologist, 2014, Volume: 19, Issue:5 Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Dis	2014
Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Oncology reports, 2015, Volume: 33, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response	2015
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. European journal of cancer (Oxford, England : 1990), 2016, Volume: 63 Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neo	2016
Timing of multikinase inhibitor initiation in differentiated thyroid cancer. Endocrine-related cancer, 2017, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Fema	2017
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer science, 2008, Volume: 99, Issue:9 Topics: Antineoplastic Agents; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Hu	2008
Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma;	2009
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer chemotherapy and pharmacology, 2009, Volume: 63 Suppl 1 Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzen	2009
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Molecular cancer therapeutics, 2010, Volume: 9, Issue:1 Topics: Animals; Antigens, Bacterial; Bacterial Toxins; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Cell	2010
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. Journal of the National Cancer Institute, 2010, Feb-24, Volume: 102, Issue:4 Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomedical Research; Carcinoma; Carcinoma,	2010
Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free radical biology & medicine, 2010, May-15, Volume: 48, Issue:10 Topics: Acetylation; Apoptosis; Breast Neoplasms; Carcinoma; Carrier Proteins; Cell Line, Tumor; Cloning, Mo	2010
Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Molecular cancer therapeutics, 2010, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Carcinoma; Drug Evaluation, Prec	2010
Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. International journal of oncology, 2010, Volume: 37, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Carcinoma; Drug Evaluation, Preclini	2010
Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:4 Topics: Acute Coronary Syndrome; Benzamides; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Fatal Outco	2011
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC cancer, 2011, Mar-24, Volume: 11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C	2011
Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. Endocrine-related cancer, 2012, Volume: 19, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidaz	2012
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell death & disease, 2012, Jan-26, Volume: 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma; Cell Line,	2012
[Endocrinology]. Revue medicale suisse, 2012, Jan-11, Volume: 8, Issue:323 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Benzenesulfonates; Carcinoma; Carcinoma, Medullary; Clini	2012
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. Thyroid : official journal of the American Thyroid Association, 2012, Volume: 22, Issue:5 Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Ou	2012
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocrine-related cancer, 2012, Volume: 19, Issue:4 Topics: Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Animals; Antineoplastic Combined Chemoth	2012
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma. International journal of cancer, 2013, Feb-01, Volume: 132, Issue:3 Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cel	2013
Sorafenib therapy decreases the clearance of thyrotropin. European journal of endocrinology, 2013, Volume: 168, Issue:2 Topics: Aged; Aged, 80 and over; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Male; Middle A	2013
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. American journal of surgery, 2012, Volume: 204, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papill	2012
Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2002, Volume: 63, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma; Domperidone; Dose Fractionation, Radiatio	2002
Studies on Ehrlich ascites cell nuclei. IV. Determination of nicotinamide adenosine dinucleotide pyrophosphorylase activity in nuclei isolated by an improved technique. Experimental cell research, 1963, Volume: 29 Topics: Adenosine; Animals; Ascites; Carcinoma; Carcinoma, Ehrlich Tumor; Cell Nucleus; NAD; Niacinamide; Ph	1963
Nicotinic acid and nicotinamide metabolism in ascites cells in vitro. The Journal of biological chemistry, 1962, Volume: 237 Topics: Animals; Ascites; Carcinoma; Carcinoma, Ehrlich Tumor; In Vitro Techniques; NAD; Niacin; Niacinamide	1962
[Complexes of 3,4-benzopyrene and various substances in aqueous solution. Action in vitro and in vivo on Ehrlich's ascites cancer cells]. Bollettino della Societa italiana di biologia sperimentale, 1962, Dec-15, Volume: 38 Topics: Animals; Ascites; Benzo(a)pyrene; Benzopyrenes; Caffeine; Carcinoma; Carcinoma, Ehrlich Tumor; Hista	1962
[ON THE EFFECT OF HYDROGEN PEROXIDE-FORMING QUINONES ON TUMOR CELLS]. Hoppe-Seyler's Zeitschrift fur physiologische Chemie, 1963, Volume: 332 Topics: Adenosine Triphosphate; Animals; Carbohydrate Metabolism; Carcinoma; Carcinoma, Ehrlich Tumor; Catal	1963
EFFECT OF NICOTINAMIDE ON GROWTH OF MOUSE EHRLICH ASCITES TUMOR. ANL-6723. ANL, 1963 Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Mice; Niacin; Niacinamide; Pharmacology; Physiological	1963
EFFECT OF ENDOTOXIN ON LIVER CARBOHYDRATE OF MICE BEARING TRANSPLANTABLE TUMORS SARCOMA 37 AND KREBS-2 CARCINOMA. Cancer research, 1964, Volume: 24 Topics: Animals; Carcinoma; Carcinoma, Krebs 2; Cortisone; Endotoxins; Iron-Dextran Complex; Liver; Liver Gl	1964
THE ROLE OF DPNASE IN THE MECHANISM OF ACTION OF AN ANTITUMOR ALKYLATING AGENT ON EHRLICH ASCITES CELLS. Proceedings of the National Academy of Sciences of the United States of America, 1964, Volume: 52 Topics: Alkylating Agents; Animals; Antineoplastic Agents; Ascites; Carbohydrate Metabolism; Carcinoma; Carc	1964
STIMULATION OF DPN TURNOVER IN ASCITES TUMOR CELLS BY LOW X-RAY DOSES. Life sciences (1962), 1965, Volume: 4 Topics: Animals; Ascites; Carcinoma; Carcinoma, Ehrlich Tumor; DNA; DNA, Neoplasm; Metabolism; N-Glycosyl Hy	1965
[ANAEROBIC GLYCOLYSIS IN EHRLICH ASCITES TUMOR CELLS. 1. ALTERATION BY ADENOSINE (MONO-DI-,TRI-)PHOSPHATE AND NICOTINAMIDE]. Zeitschrift fur klinische Chemie und klinische Biochemie, 1965, Volume: 3 Topics: Adenine Nucleotides; Adenosine; Animals; Carbohydrate Metabolism; Carcinoma; Carcinoma, Ehrlich Tumo	1965
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma;	2003
Modulation of hypoxia in murine liver metastases of colon carcinoma by nicotinamide and carbogen. Radiation research, 2005, Volume: 164, Issue:3 Topics: Animals; Carbon Dioxide; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Colonic Neop	2005
BRAF is a therapeutic target in aggressive thyroid carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-01, Volume: 12, Issue:5 Topics: Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Humans; Male; Mice;	2006
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood, 2006, Aug-15, Volume: 108, Issue:4 Topics: Benzamides; Benzenesulfonates; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Drug Res	2006
Nicotinamide extends replicative lifespan of human cells. Aging cell, 2006, Volume: 5, Issue:5 Topics: Adenosine Triphosphate; Carcinoma; Cell Division; Cell Line, Tumor; Cells, Cultured; Cellular Senesc	2006
Modification of pancreatic carcinogenesis in the hamster model. XV. Preventive effect of nicotinamide. Journal of the National Cancer Institute, 1984, Volume: 73, Issue:3 Topics: Adenoma; Animals; Carcinogens; Carcinoma; Cricetinae; Female; Male; Mesocricetus; Niacinamide; Nitro	1984
Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1998, Volume: 48, Issue:2 Topics: Actuarial Analysis; Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over	1998
Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo. International journal of radiation oncology, biology, physics, 1998, Nov-01, Volume: 42, Issue:4 Topics: Adenocarcinoma; Animals; Carbon Dioxide; Carcinoma; Cell Hypoxia; Colonic Neoplasms; Contrast Media;	1998
The measurement of radiosensitizer-induced changes in mouse tumor metabolism by 31P magnetic resonance spectroscopy. International journal of radiation oncology, biology, physics, 1991, Volume: 20, Issue:2 Topics: Animals; Carcinoma; Female; Flunarizine; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred C	1991
Establishment of three bleomycin-resistant human carcinoma cell lines and their cross-resistance to other antitumor agents. Cancer, 1988, Apr-15, Volume: 61, Issue:8 Topics: Aged; Antineoplastic Agents; Bleomycin; Carcinoma; Drug Resistance; Filipin; HeLa Cells; Humans; KB	1988
Inhibition of transfer ribonucleic acid methylase activity from several human tumors by nicotinamide and nicotinamide analogs. Biochemistry, 1972, Feb-01, Volume: 11, Issue:3 Topics: Adenocarcinoma; Aldehydes; Amines; Animals; Carbon Isotopes; Carcinoma; Carcinoma 256, Walker; Cell	1972
Nicotinamide methyltransferase and S-adenosylmethionine: 5'-methylthioadenosine hydrolase. Control of transfer ribonucleic acid methylation. Biochemistry, 1973, Nov-06, Volume: 12, Issue:23 Topics: Animals; Carbon Radioisotopes; Carcinoma; Cell Line; Chromatography, Gel; Chromatography, Thin Layer	1973
[Proceedings: Tryptophan metabolism, bladder carcinoma and smoking habits]. Zeitschrift fur klinische Chemie und klinische Biochemie, 1972, Volume: 10, Issue:4 Topics: 3-Hydroxyanthranilic Acid; Carcinoma; Humans; Kynurenine; Niacinamide; Smoking; Tryptophan; Urinary	1972

niacinamide and Carcinoma, Anaplastic